Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL

Clinical Immunology

Volumn 105, Issue 1, 2002, Pages 81-92

  Virella, G ^a   Atchley, D ^a   Koskinen, Sinikka ^a   Zheng, D ^b   Lopes Virella, Maria F ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Arteriosclerosis; Autoimmunity; Diabetes; Human oxidized LDL antibodies; Immune complexes; Immunological factors in atherosclerosis

Indexed keywords

ANTIBODY; CHOLESTEROL ESTER; IMMOBILIZED ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADSORPTION; ADULT; ANTIGEN ANTIBODY COMPLEX; ARTERIOSCLEROSIS; ARTICLE; ATHEROGENESIS; AUTOIMMUNITY; CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DIABETES MELLITUS; ERYTHROCYTE; FOAM CELL; HUMAN; HUMAN TISSUE; INFLAMMATION; MACROPHAGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION;

EID: 18644384153     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2002.5269     Document Type: Article

References (51)

1. Steinbrecher, U. P., Fisher, M., Witztum, J. L., and Curtiss, L. K., Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: Generation of antibodies specific for derivatized lysine. J. Lipid Res. 25, 1109-1116, 1984.
2. Steinbrecher, U. P., Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262, 3603- 3608, 1987.
3. Palinski, W., Yla-Herttuala, S., Rosenfeld, M. E., Butler, S. W., Socher, S. A., Parthasarathy, S., Curtiss, L. K., and Witztum, J. L., Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10, 325-335, 1990.
4. Mironova, M., Virella, G., and Lopes-Virella, M. F., Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscl. Thromb. Vasc. Biol. 16, 222-229, 1996.
5. Virella, G., Koskinen, S., Krings, G., Onorato, J. M., Thorpe, S. R., and Lopes-Virella, M., Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin. Immunol. 95, 135-144, 2000.
6. Erkkil, A. T., Närvänen, O., Lehto, S., Uusitupa, M. I. J., and Yl-Herttuala, S., Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscl. Thromb. Vasc. Biol. 20, 204-209, 2000.
7. Lehtimaki, T., Lehtinen, S., Solakivi, T., Nikkila, M., Jaakkola, O., Jokela, H., Yla-Herttuala, S., Luoma, J. S., Koivula, T., and Nikkari, T., Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscl. Thromb. Vasc. Biol. 19, 23-27, 1999.
8. Maggi, E., Chiesa, R., Melissano, G., Castellano, R., Astore, D., Grossi, A., Finardi, G., and Bellomo, G., LDL oxidation in patients with severe carotid atherosclerosis: A study of in vitro and in vivo oxidation markers. Arterioscl. Thromb. 14, 1892-1899, 1994.
9. Salonen, J. T., Yla-Herttuala, S., Yamamoto, R., Butler, S., Korpela, H., Salonen, R., Nyyssonen, K., Palinski, W., and Witztum, J. L., Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339, 883-887, 1992.
10. Boullier, A., Hamon, M., Walters-Laporte, E., Martin-Nizart, F., Mackereel, R., Fruchart, J. C., Bertrand, M., and Duriez, P., Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin. Chim. Acta 238, 1-10, 1995.
11. Festa, A., Kopp, H. P., Schernthaner, G., and Menzel, E. J., Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia. 41: 350-356, 1998.
12. Hulthe, J., Wiklund, O., Hurt-Camejo, E., and Bondjers, G., Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscl. Thromb. Vasc. Biol. 21, 269-274, 2001.
13. Virella, G., Virella, I., Leman, R. B., Pryor, M. B., and Lopes-Virella, M. F., Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23, 95-101, 1993.
14. Yla-Herttuala, S., Palinski, W., Butler, S., Picard, S., Steinberg, D., and Witztum, J. L., Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscl. Thromb. 14, 32-40, 1994.
15. Yla-Herttuala, S., Palinski, W., Rosenfeld, M. E., Parthasarathy, S., Carew, T. E., Butler, S., Witztum, J. L., and Steinberg, D., Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84, 1086-1095, 1989.
16. Orekhov, A. N., Kalenich, O. S., Tertov, V. V., Perova, N. V., Novikov Iy, D., Lyakishev, A. A., Deev, A. D., and Ruda, M., Diagnostic value of immune cholesterol as a marker for atherosclerosis. J. Cardiovasc. Risk 2, 459-466, 1995.
17. Turk, Z., Sesto, M., Skodlar, J., Ferencak, G., Turk, N., and Stavljenic-Rukavina, A., Soluble LDL-immune complexes in type 2 diabetes and vascular disease. Horm. Metab. Res. 34, 196-201, 2002.
18. Lopes-Virella, M. F., Virella, G., Orchard, T. J., Koskinen, S., Evans, R. W., Becker, D. J., and Forrest, K. Y., Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin. Immunol. 90, 165-172, 1999.
19. Orchard, T. J., Virella, G., Forrest, K. Y., Evans, R. W., Becker, D. J., and Lopes-Virella, M. F., Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48, 1454-1458, 1999.
20. Klimov, A. N., Denisenko, A. D., Popov, A. V., Nagornev, V. A., Pleskov, V. M., Vinogradov, A. G., Denisenko, T. V., Magracheva, E., Kheifes, G. M., and Kuznetzov, A. S., Lipoprotein-antibody immune complexes: Their catabolism and role in foam cell formation. Atherosclerosis 58, 1-15, 1985.
21. Klimov, A. N., Denisenko, A. D., Vinogradov, A. G., Nagornev, V. A., Pivovarova, Y. I., Sitnikova, O. D., and Pleskov, V. M., Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis 74, 41-46, 1988.
22. Mironova, M., Virella, G., Virella-Lowell, I., and Lopes-Virella, M. F., Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin. Immunol. Immunopathol. 85, 73-82, 1997.
23. Mironova, M. A., Klein, R. L., Virella, G. T., and Lopes-Virella, M. F., Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 49, 1033-1041, 2000.
24. Orekhov, A. N., and Tertov, V. V., Antibody-like immunoglobulins G against low density lipoprotein that stimulate lipid accumulation in cultured cells. In "Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia" (C. L. Malmandier, Ed.), p. 399-404, Plenum Press, New York, 1990.
25. Gisinger, C., Virella, G. T., and Lopes-Virella, M. F., Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin. Immunol. Immunopathol. 59, 37-52, 1991.
26. Griffith, R. L., Virella, G. T., Stevenson, H. C., and Lopes-Virella, M. F., Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes: A possible mechanism of foam cell formation. J. Exp. Med. 168, 1041-1059, 1988.
27. Lopes-Virella, M. F., Binzafar, N., Rackley, S., Takei, A., La Via, M., and Virella, G., The uptake of LDL-IC by human macrophages: Predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135, 161-170, 1997.
28. Lopes-Virella, M. F., and Huang, Y., Oxidized LDL-containing immune complexes stimulate mitogen-activated protein (MAP) kinase in macrophages. J. Invest. Med. 46, 232A, 1998.
29. Virella, G., Munoz, J. F., Galbraith, G. M., Gissinger, C., Chassereau, C., and Lopes-Virella, M. F., Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. Clin. Immunol. Immunopathol. 75, 179-189, 1995.
30. Huang, Y., Fleming, A. J., Wu, S., Virella, G., and Lopes-Virella, M. F., Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 20, 2533-2538, 2000.
31. Lopes-Virella, M. F., Griffith, R. L., Shunk, K. A., and Virella, G. T., Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler. Thromb. 11, 1356-1367, 1991.
32. Friguet, B., Chaffotte, A. F., Djavadi-Ohaniance, L., and Goldberg, M., Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 77, 305-309, 1985.
33. Lopes-Virella, M. F., Koskinen, S., Mironova, M., Horne, D., Klein, R., Chassereau, C., Enockson, C., and Virella, G., The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis 152, 105-113, 2000.
34. Lowry, O. H., Rosebrough, N. J., Farr, A. I., and Randall, A. J., Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275, 1951.
35. Chenais, F., Virella, G., Patrick, C. C., and Fudenberg, H. H., Isolation of soluble immune complexes by affinity chromatography using staphylococcal protein A-sepharose as substrate. J. Immunol. Methods 18, 188-192, 1977.
36. Auwerx, J., The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation. Experientia 47, 22-31, 1991.
37. Stevenson, H. C., Schlick, E., Griffith, R., Chirigos, M. A., Brown, R., Conlon, J., Kanapa, D. J., Oldham, R. K., and Miller, P., Characterization of biological response modifier release by human monocytes cultured in suspension in serum-free medium. J. Immunol. Methods 70, 245-255, 1984.
38. Hara, A., and Radin, N. S., Lipid extraction of tissues with a low-toxicity solvent. Anal. Biochem. 90, 420-426, 1978.
39. Lopes-Virella, M. F., Sherer, G. K., Lees, A. M., Wohltmann, H., Mayfield, R., Sagel, J., LeRoy, E. C., and Colwell, J. A., Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: Changes with metabolic control. Diabetologia 22, 430-436, 1982.
40. Virella, G., Biosynthesis, Metabolism, and Biological Properties of Immunoglobulins. In "Medical Immunology" (G. Virella, Ed.), 5th ed., pp. 93-104, Marcel Dekker, New York, 2001.
41. Virella, G., and Tsokos, G., Immune complex diseases. In "Medical Immunology" (G. Virella, Ed.), pp. 453-471, Marcel Dekker, New York, 2001.
42. Virella, G., Lopes-Virella, M. F., Shuler, C., Sherwood, T., Espinoza, G. A., Winocour, P., and Colwell, J. A., Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. Immunology 50, 43-51, 1983.
43. Cornacoff, J. B., Hebert, L. A., Smead, W. L., VanAman, M. E., Birmingham, D. J., and Waxman, F. J., Primate erythrocyte-immune complex-clearing mechanism. J. Clin. Invest. 71, 236-247, 1983.
44. Sherwood, T. A., and Virella, G., The binding of immune complexes to human red cells: Complement requirements and fate of the RBC-bound IC after interaction with human phagocytic cells. Clin. Exp. Immunol. 64, 195-204, 1986.
45. Cosio, F. G., Hebert, L. A., Birmingham, D. J., Dorval, B. L., Bakaletz, A. P., Kujala, G. A., Edberg, J. C., and Taylor, R. P., Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate. Clin. Immunol. Immunopathol. 42, 1-9, 1987.
46. Bengualid, V., Hatcher, V. B., Diamond, B., Blumberg, E. A., and Lowy, F. D., Staphylococcus aureus infection of human endothelial cells potentiates Fc receptor expression. J. Immunol. 145, 4279-4283, 1990.
47. Cines, D. B., Lyss, A. P., Bina, M., Corkey, R., Kefalides, N. A., and Friedman, H. M., Fc and C3 receptors induced by herpes simplex virus on cultured human endothelial cells. J. Clin. Invest. 69, 123-128, 1982.
48. Friedman, H. M., Viral infection of endothelium and the induction of Fc and C3 receptors. In "Biology of Endothelial Cells" (E. A. Jaffe, Ed.), pp. 268-274, Martinus Nijhoff, Boston, 1984.
49. MacCormac, L. P., and Grundy, J. E., Human cytomegalovirus induces an Fc γ receptor (FcγR) in endothelial cells and fibroblasts that is distinct from the human cellular FcγRs. J. Infect. Dis. 174, 1151-1161, 1996.
50. Vielma, S., Virella, G., Gorod, A. J., and Lopes-Virella, M. F., Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of Fc γ receptor II (FcγRII). Clin. Immunol., in press.
51. Bierer, B. E., Goust, J. M., and Virella, G., Cell-mediated immunity. In "Medical Immunology" (G. Virella, Ed.), pp. 193-224, Marcel Dekker, New York, 2001.